TorreyPines Cuts Jobs As Eisai Deal Ends
This article was originally published in The Pink Sheet Daily
Executive Summary
Focus turns to developing injectable and oral tezampanel for migraines.
You may also be interested in...
With Five Deals In Two Months, TorreyPines Scrambling To Preserve A Future
California biotech has out-licensed virtually everything but three clinical compounds, while exiting discovery work entirely.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.